IDEAYA Biosciences (IDYA) Share-based Compensation (2018 - 2026)
IDEAYA Biosciences (IDYA) posted Share-based Compensation of $161.6 million for Q1 2026, up 674.35% sequentially from -$28.1 million in Q4 2025, and up 67.98% YoY from $96.2 million in Q1 2025.
IDEAYA Biosciences (IDYA) Share-based Compensation (2018 - 2026) Analysis & Trends
IDEAYA Biosciences has reported Share-based Compensation for 9 years, with the latest figure at $161.6 million in Q1 2026.
- Quarterly Share-based Compensation rose 67.98% year-over-year to $161.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $161.6 million (up 67.98% YoY) and the FY2025 annual result came in at $96.2 million, up 6.65% from the prior year.
- Share-based Compensation climbed to $161.6 million in Q1 2026 per IDYA's latest filing, from -$28.1 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $161.6 million in Q1 2026 and troughed at -$28.1 million in Q4 2025.
- A 5-year average of $25.2 million and a median of $6.3 million in 2024 frame the typical range for Share-based Compensation.
- The widest YoY moves for Share-based Compensation: up 1424.08% in 2025, down 396.64% in 2025.
- Over 5 years, Share-based Compensation stood at $3.0 million in 2022, then soared by 521.48% to $18.5 million in 2023, then plunged by 48.7% to $9.5 million in 2024, then tumbled by 396.64% to -$28.1 million in 2025, then soared by 674.35% to $161.6 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $161.6 million, -$28.1 million, and $108.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | IDEAYA Biosciences | 3.50 Bn | 2.67 Bn | - | 158.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 158.30 Mn |
| Jun 30, 2026 | 158.30 Mn |
| Mar 31, 2026 | 161.60 Mn |
| Mar 31, 2026 | 161.60 Mn |
| Dec 31, 2025 | -28.14 Mn |
| Dec 31, 2025 | -28.14 Mn |
| Sep 30, 2025 | 108.40 Mn |
| Sep 30, 2025 | 108.40 Mn |
| Jun 30, 2025 | 11.87 Mn |
| Jun 30, 2025 | 11.87 Mn |
| Mar 31, 2025 | 96.20 Mn |
| Mar 31, 2025 | 96.20 Mn |
| Dec 31, 2024 | 9.49 Mn |
| Dec 31, 2024 | 9.49 Mn |
| Sep 30, 2024 | 9.22 Mn |
| Sep 30, 2024 | 9.22 Mn |
| Jun 30, 2024 | 9.73 Mn |
| Jun 30, 2024 | 9.73 Mn |
| Mar 31, 2024 | 6.31 Mn |
| Mar 31, 2024 | 6.31 Mn |